Companies
Kingdomway
a publicly listed (SZ:002626) Chinese producer of Schizochytrium-derived DHA algal oil for food-grade and supplement use; the Chinese food-grade algal DHA oil stream is standardized at roughly 40% DHA content.
- Country
- China
- Ticker
- SZ:002626
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| aquaculture-seafood | ✓ | ✓ | ✓ |
| platform-chemicals | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Kingdomway completed an issuance of convertible bonds in 2025, raising 1.28 billion RMB in net proceeds. | news.futunn.com · kingdomway.com |
| Founded | 1997 | lookchem.com |
| Headquarters | Xiamen, Fujian, China (specifically No. 299, West Yangguang Road, Haicang District) | kingdomway.com |
| Production site | Xiamen, Inner Mongolia, and Jiangsu (China); Los Angeles, Seattle, and Casa Grande (USA) | kingdomway.com |
| Capacity | Planned project for 100,000 tons of algae oil Omega-3 annually (approved, in early stages). Coenzyme Q10 capacity reached 920 tons annually in 2025. | news.futunn.com |
| Certification | ISO9001, ISO14001, HACCP, FSSC22000, FAMI-QS, HALAL, KOSHER, NSF | khsingredients.com · lookchem.com |
| Regulatory approval | Operates under Chinese food and health food regulations; U.S. facility complies with FDA cGMP standards. medium confidence | kingdomway.com · lookchem.com |
| Headcount | More than 1,200 serving staff | lookchem.com |
| Revenue | 3.365 billion RMB in 2025 | news.futunn.com · kingdomway.com |
Independent sources: khsingredients.com · lookchem.com · news.futunn.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Arachidonic acid (ARA) microbial synthesis | platform-chemicals | Medium | → |
| Microalgal omega-3 (EPA/DHA algal oils) | aquaculture-seafood | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.